Drug intelligence / Profile preview

Virna Therapeutics DUB inhibitor

Development stage: Preclinical
Lead developer: Virna Therapeutics
Modality: Small Molecules

Overview

Virna Therapeutics DUB inhibitor is an unnamed small-molecule protease inhibitor currently in preclinical development for the treatment of COVID-19. Developed by Virna Therapeutics, the drug targets deubiquitinases (DUBs) that play a critical role in the assembly and release of SARS-CoV-2 from infected cells. By inhibiting these enzymes, the therapy aims to disrupt the late stages of the viral life cycle, thereby reducing viral replication and egress. The program has successfully completed virtual library screening (VLS) and has a validated biochemical assay.

Other names: DUB Inhibitor (unnamed)Small Molecule Protease Inhibitors (DUBs)

Targets

DUB (Deubiquitinases)

Beyond the preview

Go deeper on Virna Therapeutics DUB inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virna Therapeutics DUB inhibitor.

Explore the full profile